Phillip Hunter v. Fillmore Capital Partners LLC

Court of Appeals for the Third Circuit·Decided April 1, 2025·No. 24-1606·Unpublished

Opinion

NOT PRECEDENTIAL

UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT

No. 24-1606

UNITED STATES OF AMERICA; STATE OF CALIFORNIA; STATE OF GEORGIA; STATE OF INDIANA; STATE OF MINNESOTA; STATE OF MISSOURI; STATE OF NEW JERSEY; STATE OF NORTH CAROLINA; STATE OF TENNESSEE; STATE OF WISCONSIN; COMMONWEALTH OF MASSACHUSETTS; COMMONWEALTH OF VIRGINIA EX REL.; PHILLIP HUNTER

v.

FILLMORE CAPITAL PARTNERS, LLC; FILLMORE STRATEGIC MANAGEMENT, LLC; FILLMORE STRATEGIC INVESTORS, LLC; DRUMM INVESTORS, LLC;

GGNSC HOLDINGS, LLC; GOLDEN GATE NATIONAL SENIOR CARE, LLC; GGNSC EQUITY HOLDINGS, LLC; GGNSC ADMINISTRATIVE SERVICES, LLC; GGNSC CLINICAL SERVICES, LLC; BEVERLY ENTERPRISES, INC.; BEVERLY HEALTH AND REHABILITATION SERVICES, INC.

Phillip Hunter,

Appellant

On Appeal from the United States District Court for the Eastern District of Pennsylvania (D.C. No. 2:15-cv-02134)

District Judge: Honorable Chad F. Kenney

Submitted Under Third Circuit L.A.R. 34.1(a)

November 5, 2024

BEFORE: KRAUSE, SCIRICA, and RENDELL, Circuit Judges.

(Filed: April 1, 2025)

OPINION*

RENDELL, Circuit Judge.

Appellees Fillmore Capital Partners LLC and its affiliates (collectively “Golden Living”) operate nursing homes across the United States. Appellant Phillip Hunter brought this qui tam action alleging that Golden Living engaged in fraud and violated the False Claims Act (“FCA”) and various state laws by submitting inflated claims for payment to Medicare and Medicaid. The District Court granted Golden Living’s motion to dismiss Hunter’s complaint, concluding that he failed to meet the heightened pleading standard for fraud under Federal Rule of Civil Procedure 9(b) and failed to allege a prima facie case under the FCA. We agree and will affirm.

I.

Golden Living operates 273 nursing homes across the country, including Golden Living-Riverchase in Birmingham, Alabama. Hunter, a registered nurse, worked at this facility as a weekend supervisor and weekday treatment nurse from December 2006 until he resigned in February 2007. Hunter claims that, in his two months at the nursing home, he learned that Golden Living engaged in a years-long scheme to overbill Medicare and Medicaid at each of its facilities. This alleged scheme involved Golden Living intentionally admitting high-acuity residents who required more intensive care while

*

This disposition is not an opinion of the full Court and, pursuant to I.O.P. 5.7, does not constitute binding precedent.

simultaneously understaffing the facilities. Although Golden Living billed Medicare and Medicaid for providing care to these high-acuity residents, Hunter alleges that Golden Living could not and, thus, did not provide adequate care to the residents. This, he alleges, rendered Golden Living’s requests for payment fraudulent under the FCA and state law.

In 2015, Hunter filed a sealed Complaint against eleven entities alleging violations of the FCA.1 From 2015 to July 2023, the United States filed over a dozen motions to continue to seal the Complaint while it investigated Hunter’s claims. The United States ultimately declined to intervene. Hunter then filed an Amended Complaint asserting five counts for violations of the federal FCA and twenty-three counts for state law violations. Later, the Amended Complaint was unsealed.

Golden Living filed a motion to dismiss the Amended Complaint and the District Court granted it. In opposing the motion to dismiss, Hunter principally relied on three categories of allegations to support his prima facie case under the FCA. First, Hunter cited reports that he commissioned from “workload experts, database experts, computer simulation experts, and industrial engineers.” J.A. 117 (footnote omitted). These reports, he urged, showed that Golden Living’s submissions to Medicare and Medicaid for payments were fraudulent because they included material misrepresentations that were based on “mathematical[] and human[] impossib[ilities].” Id. Second, Hunter relied upon affidavits from two nurses employed at other Golden Living facilities describing

Golden Living disputes that it controls or operates all eleven named entities. Because 1

we will affirm the District Court’s order, we need not resolve this dispute.

understaffing and purported overbilling. Third, Hunter cited his personal experience at Golden Living’s Birmingham facility, as well as his letter of resignation, in which he described an “[i]nadequate number of staff” and inability to treat residents adequately as reasons for his resignation. J.A. 63.

The District Court found these allegations insufficient to meet his burden of pleading a prima facie case of fraud under Federal Rule of Civil Procedure 9(b) and further concluded that because Hunter failed to state an FCA claim under Federal Rule of Civil Procedure 12(b)(6), it would not “exercise supplemental jurisdiction over Plaintiff’s state law claims.” United States ex rel. Hunter v. Fillmore Cap. Partners, LLC, No. 15- 2134, 2024 WL 1051971, at *10 (E.D. Pa. Mar. 11, 2024). Hunter appealed.

II.2

On appeal, Hunter essentially advances two arguments in favor of reversal: (1) the District Court erroneously imposed a higher pleading standard than required under Federal Rule of Civil Procedure 9(b), and (2) the District Court failed to accept the allegations in the Amended Complaint as true and draw all reasonable inferences in his favor as required under Federal Rule of Civil Procedure 12(b)(6). We reject both arguments.

2 The District Court had jurisdiction under 28 U.S.C §§ 1331 and 1367. We have jurisdiction under 28 U.S.C. § 1291. We review a district court’s grant of a motion to dismiss de novo. Howard Hess Dental Lab’ys Inc. v. Dentsply Int’l, Inc., 602 F.3d 237, 246 (3d Cir. 2010).

A.

Hunter first urges that the District Court erred in finding his allegations insufficiently particular under Federal Rule of Civil Procedure 9(b). An FCA plaintiff must comply with Federal Rule of Civil Procedure 9(b) and plead his fraud claims with particularity. United States ex rel. Schmidt v. Zimmer, Inc., 386 F.3d 235, 242 n.9 (3d Cir. 2004) (citing United States ex rel. LaCorte v. SmithKline Beecham Clinical Lab’ys, Inc., 149 F.3d 227, 234 (3d Cir. 1998)). To meet the pleading standard of Federal Rule of Civil Procedure 9(b), the plaintiff must allege “particular details of a scheme to submit false claims paired with reliable indicia that lead to a strong inference that claims were actually submitted.” Foglia v. Renal Ventures Mgmt., LLC, 754 F.3d 153, 156 (3d Cir. 2014) (emphasis added) (citations and internal quotation marks omitted). While a plaintiff need not produce “representative samples” of the alleged fraudulent conduct, id. at 156, he must allege the “who, what, when, where, and how” of the fraudulent scheme, United States ex rel. Moore & Co., P.A. v. Majestic Blue Fisheries, LLC, 812 F.3d 294, 307 (3d Cir. 2016) (citation and internal quotation marks omitted). However, “an inference of illegality based on facts that could plausibly have either a legal or illegal explanation would be insufficient to meet Rule 9(b)’s burden, because . . . the possibility of a legitimate explanation undermines the strength of the inference of illegality.” United States v. Omnicare, Inc., 903 F.3d 78, 92 (3d Cir. 2018) (emphasis added) (citing Foglia, 754 F.3d at 158).

Free access — add to your briefcase to read the full text and ask questions with AI

Phillip Hunter v. Fillmore Capital Partners LLC, (3d Cir. 2025).

Phillip Hunter v. Fillmore Capital Partners LLC (Phillip Hunter v. Fillmore Capital Partners LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Mayer v. Belichick
605 F.3d 223 (Third Circuit, 2010)
Phillips v. County of Allegheny
515 F.3d 224 (Third Circuit, 2008)
Thomas Foglia v. Renal Ventures Management
754 F.3d 153 (Third Circuit, 2014)
Hutchins v. Wilentz, Goldman & Spitzer
253 F.3d 176 (Third Circuit, 2001)
United States Ex Rel. Schmidt v. Zimmer, Inc.
386 F.3d 235 (Third Circuit, 2004)
United States v. Omnicare, Inc.
903 F.3d 78 (Third Circuit, 2018)
United States ex rel. Gohil v. Sanofi-Aventis U.S. Inc.
96 F. Supp. 3d 504 (E.D. Pennsylvania, 2015)